208 related articles for article (PubMed ID: 28650566)
21. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease.
Ueda Y; Kamiya CA; Horiuchi C; Miyoshi T; Hazama R; Tsuritani M; Iwanaga N; Neki R; Ikeda T; Yoshimatsu J
J Obstet Gynaecol Res; 2019 Feb; 45(2):382-388. PubMed ID: 30259601
[TBL] [Abstract][Full Text] [Related]
23. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
24. A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant.
Juliato CRT; Stahlschmidt P; Fernandes A; Monteiro I; Bahamondes L
Contraception; 2018 Sep; 98(3):252-254. PubMed ID: 29746814
[TBL] [Abstract][Full Text] [Related]
25. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Lethaby A; Hussain M; Rishworth JR; Rees MC
Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
[TBL] [Abstract][Full Text] [Related]
26. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
27. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
[TBL] [Abstract][Full Text] [Related]
28. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Romero SA; Young K; Hickey M; Su HI
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
[TBL] [Abstract][Full Text] [Related]
29. Pregnancy during the use of levonorgestrel intrauterine system.
Backman T; Rauramo I; Huhtala S; Koskenvuo M
Am J Obstet Gynecol; 2004 Jan; 190(1):50-4. PubMed ID: 14749634
[TBL] [Abstract][Full Text] [Related]
30. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
Nelson AL
Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
[TBL] [Abstract][Full Text] [Related]
31. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
Gardyszewska A; Czajkowski K
Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
[TBL] [Abstract][Full Text] [Related]
32. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
33. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas.
Bahamondes MV; Hidalgo MM; Bahamondes L; Monteiro I
Contraception; 2011 Nov; 84(5):e11-6. PubMed ID: 22018132
[TBL] [Abstract][Full Text] [Related]
34. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Selim MF; Hussein AF
Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
[TBL] [Abstract][Full Text] [Related]
35. Pain and bleeding pattern related to levonorgestrel intrauterine system (LNG-IUS) insertion.
Van Schoubroeck D; Van den Bosch T; Ameye L; Veldman J; Hindryckx A; Werbrouck E; Timmerman D
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):154-6. PubMed ID: 24029596
[TBL] [Abstract][Full Text] [Related]
36. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
[TBL] [Abstract][Full Text] [Related]
37. A pilot study on the acceptability of levonorgestrel-releasing intrauterine device by young, single, nulliparous Chinese females following surgical abortion.
Li CF; Lee SS; Pun TC
Contraception; 2004 Mar; 69(3):247-50. PubMed ID: 14969674
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in contraception.
Trussell J; Hassan F; Henry N; Pocoski J; Law A; Filonenko A
Contraception; 2014 May; 89(5):451-9. PubMed ID: 24576791
[TBL] [Abstract][Full Text] [Related]
39. Two-week postpartum intrauterine contraception insertion: a study of feasibility, patient acceptability and short-term outcomes.
Zerden ML; Stuart GS; Charm S; Bryant A; Garrett J; Morse J
Contraception; 2017 Jan; 95(1):65-70. PubMed ID: 27554014
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.
Graner S; Mc Taggart J; Nordström F; Melander E; Widenberg J; Kopp Kallner H
Acta Obstet Gynecol Scand; 2019 Jul; 98(7):937-943. PubMed ID: 30737766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
